EU green light for Novartis’ Rydapt
The European Commission has approved Novartis’ Rydapt to treat a certain form of acute myeloid leukaemia (AML) as well as three other rare diseases.
Read More
Tag: systemic mastocytosis
60% response rate with Novartis’ rare blood cancer drug
A mid-stage trial assessing Novartis’ experimental rare blood cancer (midostaurin) has shown high response rates in patients with systemic mastocytosis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
